Coral Labs. Share Price ₹578 | P/E 11.0

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Coral Labs.

Quarter-by-quarter operating performance

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales +	24.73	11.44	13.55	23.15	18.08	28.89	31.66	32.23	22.99	28.13	18.82	19.03	21.56
Expenses +	23.88	13.52	11.81	17.00	15.98	22.64	20.92	25.72	16.67	25.44	16.64	14.09	19.67
Operating Profit	0.85	-2.08	1.74	6.15	2.10	6.25	10.74	6.51	6.32	2.69	2.18	4.94	1.89
OPM %	3.44%	-18.18%	12.84%	26.57%	11.62%	21.63%	33.92%	20.20%	27.49%	9.56%	11.58%	25.96%	8.77%
Other Income +	1.54	1.16	1.29	1.81	1.37	2.00	1.56	2.54	2.52	1.71	2.05	3.03	2.49
Interest	0.11	0.02	0.00	0.00	0.00	0.00	0.03	0.01	0.02	0.04	0.06	0.10	0.00
Depreciation	0.50	0.68	0.55	0.44	0.49	0.50	0.49	0.51	0.50	0.51	0.45	0.45	0.69
Profit before tax	1.78	-1.62	2.48	7.52	2.98	7.75	11.78	8.53	8.32	3.85	3.72	7.42	3.69
Tax %	51.69%	-45.06%	26.21%	20.21%	27.52%	25.16%	25.21%	25.21%	26.08%	26.49%	31.18%	21.56%	24.93%
Net Profit +	0.86	-0.89	1.84	6.00	2.16	5.79	8.80	6.38	6.14	2.83	2.56	5.82	2.78
EPS in Rs	2.41	-2.49	5.15	16.79	6.05	16.21	24.63	17.86	17.19	7.92	7.17	16.29	7.78

Financials of Coral Labs.

Annual income statement trend

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	51	59	77	95	92	91	71	97	76	78	84	115	88
Expenses +	41	47	60	72	77	79	65	81	67	74	67	89	76
Operating Profit	10	12	16	23	15	12	5	16	8	4	16	26	12
OPM %	20%	21%	21%	24%	17%	14%	8%	16%	11%	5%	19%	23%	13%
Other Income +	1	3	3	3	4	5	6	4	6	7	6	8	9
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1	3	2	2	2	2	2	2	2	2	2	2	2
Profit before tax	10	12	17	25	18	16	9	18	12	8	21	32	19
Tax %	21%	22%	29%	34%	31%	34%	22%	23%	24%	22%	24%	26%
Net Profit +	8	10	12	16	12	10	7	14	9	6	16	24	14
EPS in Rs	22.03	26.79	34.71	45.63	34.85	28.61	19.96	37.93	25.33	18.05	44.20	67.63	39.16
Dividend Payout %	9%	9%	9%	11%	6%	7%	0%	0%	0%	0%	0%	0%

Financials of Coral Labs.

Capital structure and asset base

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	4	4	4	4	4	4	4	4	4	4	4	4	4
Reserves	47	56	67	106	113	110	112	133	152	151	174	198	210
Borrowings +	0	1	0	2	2	1	6	6	6	0	0	4	1
Other Liabilities +	10	12	19	20	22	21	23	25	28	20	28	25	19
Total Liabilities	60	72	89	131	140	136	144	168	190	174	206	229	233
Fixed Assets +	20	19	18	18	22	23	23	21	24	25	24	23	24
CWIP	0	0	0	0	0	0	0	0	2	0	0	2	14
Investments	1	1	5	39	45	28	25	33	46	41	50	52	57
Other Assets +	40	52	67	74	73	84	97	112	118	108	132	152	138
Total Assets	60	72	89	131	140	136	144	168	190	174	206	229	233

Financials of Coral Labs.

Operating, investing and financing cash movement

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	1	0	5	11	13	-1	-4	1	6	13	-5	-1
Cash from Investing Activity +	1	-0	-3	-10	-13	3	-2	-0	-6	-3	1	-0
Cash from Financing Activity +	0	-0	-0	0	-3	-1	4	0	0	-6	0	3
Net Cash Flow	2	-0	2	1	-2	1	-2	1	0	4	-4	1
Free Cash Flow	1	-1	4	9	9	-4	-5	-0	1	11	-6	-4
CFO/OP	29%	30%	70%	85%	124%	31%	-59%	28%	127%	383%	-4%	23%

Financials of Coral Labs.

Working capital efficiency and return ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	109	152	132	117	125	122	178	148	184	109	123	107
Inventory Days	97	110	110	155	120	116	176	158	169	100	149	68
Days Payable	61	66	80	75	87	91	129	108	81	34	130	46
Cash Conversion Cycle	145	196	162	197	157	146	225	198	272	176	142	129
Working Capital Days	158	194	179	164	161	171	241	178	222	221	183	140
ROCE %	21%	22%	27%	28%	16%	13%	8%	13%	7%	5%	13%	17%

Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Coral Labs. Share Price & Earnings Call Analysis